NCT01541475

Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Ewha Womans University · Academic / Other
• Sex: All
• Age: 20 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The current study is being conducted in patients with major depression. The study aims to 1) investigate the combined effects of selective serotonin reuptake inhibitor (SSRI) and bupropion compared to SSRI alone on the improvements of depressive symptoms, fatigue, hypersomnia, and neurocognitive functions, 2) observe structural/functional/chemical changes using magnetic resonance imaging (MRI), 3) and examine a relationship between the improvements of depressive symptoms, fatigue, and hypersomnia and the neural changes.

Conditions

• Major Depressive Disorder

Interventions

Type	Name	Description
DRUG	Bupropion, Escitalopram	Week 0-1: Escitalopram 10mg, Bupropion 150mg Week 2-3: Escitalopram 10mg, Bupropion 300mg Week 4-8: Escitalopram 20mg, Bupropion 300mg
DRUG	Escitalopram	Week 0-3: Escitalopram 10mg Week 4-8: Escitalopram 20mg

Timeline

• Start date: 2009-03-01
• Primary completion: 2011-01-01
• Completion: 2011-01-01
• First posted: 2012-03-01
• Last updated: 2014-04-10

Locations

1 site across 1 country: South Korea